GNI Group Ltd
TSE:2160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GNI Group Ltd
Long-Term Debt
GNI Group Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
Long-Term Debt
¥3B
|
CAGR 3-Years
167%
|
CAGR 5-Years
68%
|
CAGR 10-Years
20%
|
|
|
3
|
3-D Matrix Ltd
TSE:7777
|
Long-Term Debt
¥275.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Long-Term Debt
¥1.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
0%
|
|
|
PeptiDream Inc
TSE:4587
|
Long-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Long-Term Debt
¥10B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Long-Term Debt
¥76.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-13%
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Long-Term Debt?
Long-Term Debt
3B
JPY
Based on the financial report for Dec 31, 2025, GNI Group Ltd's Long-Term Debt amounts to 3B JPY.
What is GNI Group Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
20%
Over the last year, the Long-Term Debt growth was 56%. The average annual Long-Term Debt growth rates for GNI Group Ltd have been 167% over the past three years , 68% over the past five years , and 20% over the past ten years .
